Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05143970
Other study ID # CHANCES-IPC 2021-008
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date January 21, 2022
Est. completion date February 2026

Study information

Verified date April 2023
Source Institut Paoli-Calmettes
Contact DOMINIQUE GENRE
Phone 0491223778
Email drci.up@ipc.unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

CHANCES-IPC 2021-008 is First In Human, Phase I, multicenter, European study evaluating an anti-CD73, IPH5301 in advanced and/or metastatic cancer. The trial will be conducted in two parts, Part I- Dose escalation: This part aims to identify the maximum tolerated dose (MTD) of IPH5301 agent in monotherapy and recommended phase 2 dose (RP2D) for future trials, followed by a safety expansion study part cohort. Part II- Expansion cohort: A total of 12 HER2+ cancer patients, respectively 6 breast cancer patients and 6 gastric cancer patients, is planned to be enrolled into the next expansion cohort to select a recommended dose of IPH5301 to be administered in combination with chemotherapy and trastuzumab for evaluation in future trials with selected advanced solid tumors.


Recruitment information / eligibility

Status Recruiting
Enrollment 27
Est. completion date February 2026
Est. primary completion date March 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Main Inclusion Criteria: - Patients with incurable advanced and/or metastatic cancer. - Patients with any of the following cancers: 1. In dose escalation: carcinoma of the breast, stomach, esophagus, pancreas, endometrium, ovary or lung. 2. In cohort expansion (HER2-positive): carcinoma of the breast and gastric/gastro-esophageal that express HER2 (2 cohorts) . Eligibility is based on HER2 overexpression as determined locally. - Prior treatment with at least one prior systemic therapy in the advanced metastatic setting 1. Dose escalation: no limit on number of prior systemic therapies and considered as failing standard therapeutic alternatives and candidate to a phase I study by a multi-disciplinary tumor board. 2. Cohort expansion: patients must have previously re-ceived (or be considered as non-eligible to) all authorized standard treatments - Breast cancer: patient must have received prior (or be considered as ineligible to) trastuzumab pertuzumab, trastuzumab emtansine, trastuzumab deruxtecan and capecitabine+anti-HER2 (trastuzumab, lapatinib or trastuzumab tucatinib) according to label. - Gastric cancer: patient must have received (or be con-sidered as ineligible to) prior treatment with platinum salts and trastuzumab. - Presence of at least one measurable lesion by RECIST outside of the CNS. - At least 18 years of age. - ECOG performance status of =1. - For patients included in cohort expansion, adequate echocar-diogram, with a left ventricular ejection fraction =55%. Patients with a history of LVEF decline (< 50%) on anti-HER2 treatment will not be allowed to participate. - For patients included in the cohort expansion, feasibility of obtaining tumor biopsy at study entry. - All non-hematological AEs related to prior therapy must have completely resolved or improved to Grade 1 prior to screening for this study (except for alopecia). Exclusion Criteria: - Prior treatment with other monoclonal antibodies or small mol-ecules targeting CD73 or the adenosine pathway. - Patients with known spinal cord compression. - Patients with grade 2 or higher peripheral neuropathy. - Symptomatic, untreated, or actively progressing central nerv-ous system (CNS) metastases. Patients with suspected CNS involvement at screening should have an magnetic resonance imaging (MRI) (preferred) or computed tomography (CT) each preferably with IV contrast of the brain prior to study entry to rule them out. Asymptomatic patients with treated CNS lesions are eligible, provided that definied criteria are met - Known allergic reactions attributed to compounds of similar product. - Patients with dyspnea at rest and history of pneumonit-is/interstitial lung disease. - Patients with any serious underlying medical condition that would impair the subject from receiving or tolerating the planned treatment. - Concurrent enrollment in another clinical trial, unless it is an non-interventional clinical study or the follow-up period of an interventional study. - Any concurrent treatment with any anti-cancer agents or drugs that could have anti-tumor effects. - Active auto-immune disease within the past 2 years. - = Grade 3 immune related AE or an immune-related neuro-logic or ocular AE of any grade while receiving prior immunotherapy. - Subjects who have undergone major surgery <28 days prior to starting study drug. - Treatment with any conventional or investigational anticancer therapy within 28 days prior to day 1 of study treatment. - Receipt of live attenuated vaccine or SARS-CoV-2 vaccine within 30 days prior to the first dose of study drug - Primary immunodeficiency and/or history of allogenic transplantation. - Current uncontrolled infection. - Hepatitis B, C or HIV-positive patients. - Subjects with a history of other active invasive malignancies during the past three years with the exception of those with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%) and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localised prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer). - Pregnant or breastfeeding women. - Participants with abnormal coagulation profiles or any history of coagulopathy within the 6 months prior to the first dose of IMP, as well as history of deep vein thrombosis, pulmonary embolism, cerebrovascular accident or other arterial thrombus. Participants being treated with an anticoagulant (eg, warfarin or heparin) for a thrombotic event that occurred more than 6 months before en-rollment, or for an otherwise stable and allowed medical condition (eg, well-controlled atrial fibrillation), provided that dose and co-agulation parameters (as defined by local standard of care) are stable for at least 1 month prior to the first dose of IMP are allowed. - Subjects with dementia or altered mental status that would preclude understanding and rendering of informed consent document.

Study Design


Intervention

Drug:
IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB
Part I-Dose escalation Patients will receive IPH5301 alone on day 1 (Week 1). Treatment will be administered every 2 weeks until progression or unacceptable toxicity or other reasons requiring treatment discon-tinuation, for a maximum duration of 12 months. Part II- Expansion cohort Patients will receive IPH5301 at a recommended dose (RP2D) or a next lower dose (RP2D-1)in combination with trastuzumab and paclitaxel, at day 1 and every 2 weeks up to 6 cycles of paclitaxel. The RP2D dose will not exceed the designated maximum tolerated dose (MTD).

Locations

Country Name City State
France Institut Paoli Calmettes Marseille

Sponsors (2)

Lead Sponsor Collaborator
Institut Paoli-Calmettes Innate Pharma

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of dose limiting toxicity (DLT) of IPH5301 in monotherapy in the dose escalation and in combination with paclitaxel and trastuzumab in the expansion cohort DLTs would include any grade 3 toxicity or higher that occurs during the first 4 weeks from the first injection of IPH5301, with the some exceptions 1 month
See also
  Status Clinical Trial Phase
Withdrawn NCT04872608 - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Phase 1
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Completed NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Phase 1
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2